GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (OTCPK:BMXMF) » Definitions » Additional Paid-In Capital

BioMerieux (BioMerieux) Additional Paid-In Capital : $3,730 Mil(As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is BioMerieux Additional Paid-In Capital?


BioMerieux's quarterly additional paid-in capital increased from Dec. 2022 ($3,244 Mil) to Jun. 2023 ($3,701 Mil) and increased from Jun. 2023 ($3,701 Mil) to Dec. 2023 ($3,730 Mil).

BioMerieux's annual additional paid-in capital increased from Dec. 2021 ($2,861 Mil) to Dec. 2022 ($3,244 Mil) and increased from Dec. 2022 ($3,244 Mil) to Dec. 2023 ($3,730 Mil).

BioMerieux Additional Paid-In Capital Historical Data

The historical data trend for BioMerieux's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMerieux Additional Paid-In Capital Chart

BioMerieux Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,148.11 2,681.87 2,860.79 3,243.86 3,729.66

BioMerieux Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,860.79 3,355.07 3,243.86 3,701.30 3,729.66

BioMerieux Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

BioMerieux Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of BioMerieux's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

BioMerieux (BioMerieux) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (OTCPK:BMXMF) » Definitions » Additional Paid-In Capital
Comparable Companies
XPAR:ERF XPAR:LBIRD XPAR:ALPRE TSE:2309 TMO DHR IQV IDXX XSWX:LONN A MTD ICLR ILMN WAT SHSE:603259 LH DGX CRL RVTY EXAS
Traded in Other Exchanges
BIMp:UK 0RUG:UK BIM:France EYWN:Germany BIM:Austria
Address
Marcy l’Etoile, Lyon, FRA, 69280
Website
http://www.biomerieux.com
BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (38% of 2021 sales), microbiology (31%), immunoassays (14%), and industrial applications (about 17%). The Americas account for the largest portion of the firm's revenue (49%), followed by Europe, the Middle East, and Africa (33%), and Asia-Pacific (18%). BioMerieux is headquartered in Marcy-l'Etoile, France.

BioMerieux (BioMerieux) Headlines

From GuruFocus

bioM�rieux Introduces GENE-UP� ENVIROPRO�

By PRNewswire PRNewswire • 02-02-2023

French multidisciplinary consortium ARPEGE awarded public funding of close to �9 million to fight antibiotic resistance

By PRNewswire PRNewswire • 01-06-2022